TTTony Tse

Tony Tse

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Tony Tse has a total of 87 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Gender Eligibility Descriptions for Clinical Trials—Reply

    by Swapna Mohan, Tony Tse

    In Reply Our Research Letter analyzed free-text entries for the optional ClinicalTrials.gov data element, Gender Eligibility Description, as provided by

  • Open Access

    Approach for reporting master protocol study designs on ClinicalTrials.gov: qualitative analysis

    by Rebecca J Williams, Heather D Dobbins, Tony Tse, Sandy D Chon, David Loose, Gisele A Sarosy, Sheila A Prindiville, Frank W Rockhold, Deborah A Zarin

    Objective To describe an approach for reporting master protocol research programs (MPRPs) that is consistent with existing good reporting practices and that uses structured information to convey the overall master protocol and design of each substudy. Design Qualitative analysis. Data sources ClinicalTrials.gov trial registry. Main outcome measures Established goals and related practices of the trial reporting system were outlined, examples and key characteristics of MPRPs were reviewed, and specific challenges in registering and reporting summary results to databases designed for traditional clinical trial designs that rely on a model of one study per protocol were identified. Results A reporting approach is proposed that accommodates the complex study design of MPRPs and their results. This approach involves the use of separate registration records for each substudy within one MPRP protocol (with potential exceptions noted). Conclusions How the proposed approach allows for clear, descriptive, structured information about each substudy’s prespecified design and supports timely reporting of results after completion of each substudy is described and illustrated. Although the focus is on reporting to ClinicalTrials.gov, the approach supports broader application across trial registries and results databases. This paper is intended to stimulate further discussion of this approach among stakeholders, build awareness about the need to improve reporting of MPRPs, and encourage harmonization across trial registries globally.


  • List of Contributors

    by Paul S. Albert, Elizabeth A. Bartrum, Karen E. Berliner, Juliana Blome, Enriqueta Bond, Valerie H. Bonham, Craig B. Borkowf, John T. Burklow, Robert M. Califf, Leighton Chan, et al.

  • Update on Trial Registration 11 Years after the ICMJE Policy Was Established

    by Deborah A. Zarin, Tony Tse, Rebecca J. Williams, Thiyagu Rajakannan

    Laws and policies to establish a global trial reporting system have greatly increased the transparency and accountability of the clinical research enterprise. The three components of the trial reporting system are trial registration, reporting of aggregate results, and sharing of individual participant data.1 Trial registration is foundational to our understanding and interpretation of trial results, because it requires that information be provided about all relevant clinical trials (to put results in a broad context) and their prespecified protocol details (to ensure adherence to the scientific plan).


  • ClinicalTrials.gov and Drugs@FDA: A Comparison of Results Reporting for New Drug Approval Trials

    by Lisa M. Schwartz, Steven Woloshin, Eugene Zheng, Tony Tse, Deborah A. Zarin

    Pharmaceutical companies and other trial sponsors must submit certain trial results to ClinicalTrials.gov. The validity of these results is unclear. To validate results posted on ClinicalTrials.gov against publicly available U.S. Food and Drug Administration (FDA) reviews on Drugs@FDA. ClinicalTrials.gov (registry and results database) and Drugs@FDA (medical and statistical reviews). 100 parallel-group, randomized trials for new drug approvals (January 2013 to July 2014) with results posted on ClinicalTrials.gov (15 March 2015). 2 assessors extracted, and another verified, the trial design, primary and secondary outcomes, adverse events, and deaths. Most trials were phase 3 (90%), double-blind (92%), and placebo-controlled (73%) and involved 32 drugs from 24 companies. Of 137 primary outcomes identified from ClinicalTrials.gov, 134 (98%) had corresponding data at Drugs@FDA, 130 (95%) had concordant definitions, and 107 (78%) had concordant results. Most differences were nominal (that is, relative difference <10%). Primary outcome results in 14 trials could not be validated. Of 1927 secondary outcomes from ClinicalTrials.gov, Drugs@FDA mentioned 1061 (55%) and included results data for 367 (19%). Of 96 trials with 1 or more serious adverse events in either source, 14 could be compared and 7 had discordant numbers of persons experiencing the adverse events. Of 62 trials with 1 or more deaths in either source, 25 could be compared and 17 were discordant. Unknown generalizability to uncontrolled or crossover trial results. Primary outcome definitions and results were largely concordant between ClinicalTrials.gov and Drugs@FDA. Half the secondary outcomes, as well as serious events and deaths, could not be validated because Drugs@FDA includes only “key outcomes” for regulatory decision making and frequently includes only adverse event results aggregated across multiple trials. National Library of Medicine.


  • Open Access

    Sharing Individual Participant Data (IPD) within the Context of the Trial Reporting System (TRS)

    by Deborah A. Zarin, Tony Tse

    Deborah Zarin and Tony Tse of ClinicalTrials.Gov consider how sharing individual participant data can and cannot help improve the reporting of clinical trials.


  • Trial-Results Reporting and Academic Medical Centers

    by Deborah A. Zarin, Tony Tse, Joseph S. Ross

    Reporting of aggregate results helps mitigate disclosure biases affecting medical research.1 Although the reporting of summary results is currently mandated by the Food and Drug Administration Amendments Act of 2007 (FDAAA),2 published findings suggest underreporting.3 Two recent proposals are aimed at improving public reporting of aggregate results. These are a Notice of Proposed Rulemaking (NPRM)4 to expand FDAAA requirements to include the results of trials of unapproved products, and a draft policy requiring the results of all National Institutes of Health (NIH)–funded trials, including those not subject to the FDAAA.5 Noncompliance with either requirement would carry a risk of NIH-funding loss and other financial penalties under the FDAAA. Herein, we use data from ClinicalTrials.gov (www.clinicaltrials.gov) to estimate the proportion of trials sponsored by nonprofits, mostly academic medical centers (AMCs), that would be subject to one or both of the recently proposed reporting requirements. We chose this subset because rates of results reporting for trials sponsored by AMCs are currently low and lag behind rates for industry-sponsored trials.3


    • 5 July 2013
      • Vol. 35  (3) , 19

    Clarification about ClinicalTrials.gov.

    by Deborah A Zarin, Tony Tse


  • Unambiguous Identification of Obesity Trials

    by Deborah A. Zarin, Tony Tse

    Colman et al. (Oct. 25 issue)1 describe trial results underlying approval of two weight-management drugs by the Food and Drug Administration. However, their table included noninformative terms (e.g., “study 1”) without citing publications or ClinicalTrials.gov records. The materials that were referenced2,3 used only acronyms (e.g., BLOOM) and internal identifiers (e.g., OB-301) — neither of which could be linked to the terms in the table. Using ClinicalTrials.gov (www.clinicaltrials.gov), we identified six studies of lorcaserin for obesity4 and nine studies of phentermine and topiramate for obesity5 (as of October 15, 2012). Only Colman et al. could confirm the likely matches ( Table 1 ).